Therapeutic for Traumatic Brain Injury Using Mitochondria-Targeted Nanoparticles
- *Abstract
-
Application
- Treatment of traumatic brain injury
- Diagnosis of brain-related injuries
ProblemsAddressed (benefits/advantages)
- Nanoparticle delivery system has been optimizedto cross the blood-brain-barrier to improve efficacy of neuroprotective drugtreatments
- Combines both antioxidant and anti-inflammatorycomponents, reducing oxidative stress and local inflammation, allowing for theinjured area of the brain to be repaired by neural stem cells
TechnologySummary
Between 1.2-2 millionAmericans sustain a TBI each year. Inthe US alone, it is estimated that TBI is responsible for 50,000 deaths and235,000 hospitalizations annually. TheTBI secondary injury cascade has proven to be a complex series of mechanismsand events that lead to the destruction of brain tissue at the cellular levelwith the two major components being the formation of free radicals and immuneresponse. Neuroprotectants that inhibitsecondary injury cascades have been tested in a number of phase II and IIIclinical trials. However, despitepromising data in preclinical rodent animal models and early phase randomizedand double blinded trials, no neuroprotective treatment option exists thatleads to improved neurological outcomes. One potential method to improve efficacy is to improve therapeuticdelivery through approaches that are better able to cross the blood-brain barrier(BBB), better target cells and cellular compartments of interest.
Theinventors have discovered the therapeutic potential of a highly lipophilicmitochondria-targeted nanoparticle that is able to cross the blood brainbarrier. This nanoparticle is loadedwith an antioxidant/anti-inflammatory cocktail therapy and has shown positiveresults in a mammalian model of TBI. This nanoparticle platform can penetrate the blood brain barrier bothduring homeostasis and after TBI, allowing for delivery of a variety ofdifferent therapeutics to treat TBI. Once local inflammation and oxidative stress are reduced, the injuredarea of the brain can be repaired by delivering neural stem cells.
Inventors
· Shanta Dhar, Ph.D.
Dr. Dhar’s research interests lie at the interface ofchemistry and biology with particular emphasis on nanocarrier-mediatedintracellular delivery of payloads for potential applications in variousdiseases.
- Franklin West, Associate Professor
- Sean Marrache, Graduate Student
- Emily Baker, Graduate Student
TechnologyDevelopment and IP Status
· Patentpending in US, Europe and Japan (PCT Publication WO 2016/022462)
· Discoveryand pre-clinical development stage
- *IP Issue Date
- None
- *IP Type
- Utility
- 國家
- Not Applicable (PCT App)
- 申請號碼
- WO 2016/022462
- 國家/地區
- 美國
